Dear Editor, Thank you for the opportunity to respond to the comments of Petrella et al. [1] , whom we kindly thank for reading and commenting on our paper.
In our article entitled "Endobronchial treatment for bronchial carcinoid: patient selection and predictors of outcome," [2] we describe how patients can be selected for endobronchial treatment as an initial treatment modality for patients with bronchial carcinoids. Because radical treatment is vital, the endobronchial treatment, if unsuccessful, is followed by radical surgical resection. This strategy is performed in close cooperation with the thoracic surgeons, and all patients are discussed in the multidisciplinary thoracic tumor board prior to treatment.
Petrella et al. [1] find it doubtful that we propose endobronchial treatment as a first-line treatment because the success rate for intraluminal treatment is only 72%, and no survival data are presented. We would like to point out that endobronchial treatment cannot be compared with surgical resection as a single treatment because unsuccessful endobronchial treatment is always followed by radical surgical resection. In a previous publication, the longterm survival data of our cohort were presented [3] . The 5-year overall and disease-specific survival were 97 and 100%, respectively, and the 10-year overall and disease-specific survival for this combined treatment strategy were 80 and 97%, respectively [3] . Bearing these reassuring survival data in mind, we sought to further improve the selection of patients, which resulted in the current paper. Mortality was reported in the online data supplement. After successful endobronchial treatment, 8 patients died, but all of other causes (8/61, 13%). After unsuccessful endobronchial 
